Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Impact BioMedical, Inc. (IBO) AI Stock Analysis

IBO

Impact BioMedical, Inc.

(NYSE MKT:IBO)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Negative Factors

Impact BioMedical, Inc. (IBO) vs. SPDR S&P 500 ETF (SPY)

-80%-60%-40%-20%0%20%40%60%IBO-40.47%SPY+12.20%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$34.26M
Dividend Yield
―
Average Volume (3M)
16.25K
Price to Earnings (P/E)
-3.3
Beta (1Y)
2.55
Revenue Growth
400.00%
EPS Growth
97.00%
Country
US
Employees
2
Sector
General
Sector Strength
55
Industry
Biotechnology

Impact BioMedical, Inc. Business Overview & Revenue Model

Company Description

Houston, Texas-based Impact BioMedical Inc., founded in 2018, focuses on discovering and developing innovative products and therapeutic options for both specialty biopharmaceuticals and consumer healthcare markets. The company features several key te...

Impact BioMedical, Inc. Risk Analysis

Impact BioMedical, Inc. disclosed 26 risk factors in its most recent earnings report. Impact BioMedical, Inc. reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

Impact BioMedical, Inc. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IBO against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
NCELNCEL42Neutral$13.73M7.5421.75%―――
SCNISCNI40Underperform$268.82K0.00-26.63%―30.12%-165.46%

* General Sector Average

Performance Comparison

-100%-50%0%IBOSCNIADTXNCELVRAXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IBO and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IBOImpact BioMedical, Inc.4.01-2.71-40.29%
SCNIScinai Immunotherapeutics Ltd. Sponsored Adr0.47-11.13-95.91%
ADTXAditxt, Inc.0.04-1231.16-100.00%
NCELNewcelx Ltd.2.49-2.21-47.02%
VRAXVirax Biolabs Group Ltd. Class A1.10-11.69-91.40%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.